CoMentis raises $20 million for Alzheimer’s drugs
CoMentis has raised $20 million in a fourth round of funding to create drugs to fight Alzheimer’s disease, age-related macular degeneration (a leading cause of blindness in the elderly), and cognitive brain disorders.
The South San Francisco company has two technology platforms: aspartic protease inhibitors, including beta-secretase inhibitors for Alzheimer’s disease; and nicotinic acetylcholine receptor (nAChR) agonists and antagonists for the treatment of angiogenesis mediated diseases and cognitive disorders.
CoMentis currently has three drugs in the works for Alzheimer’s treatment. Investors in the round include: Scott Harkonen, John Donovan, Muralitharan Kengatharan, A. Barr Dolan, Dennis Henner, Robert McNeil, John Higgins, Sanderling Venture Partners VI, Clarus Lifesciences I, Astellus Pharma, John P. Cooke, Robin J. Cook, Index Ventures III, and Jersey St. Helier.
Next Story: Enquisite raises $3.2 million round for search analytics service
Previous Story: Acumentrics receives $15.6M grant for solid oxide fuel cells
About the Author, Dean Takahashi
Dean is lead writer for GamesBeat at VentureBeat. He covers video games, security, chips and a variety of other subjects. Dean previously worked at the San Jose Mercury News, the Wall Street Journal, the Red Herring, the Los Angeles Times, the Orange County Register and the Dallas Times Herald. He is the author of two books, Opening the Xbox and the Xbox 360 Uncloaked. Follow him on Twitter at @deantak, and follow VentureBeat on Twitter at @venturebeat.